Abstract 457P
Background
Cancer patients have a significantly higher risk of developing venous thromboembolism (VTE) compared to the general population. But there are no data on the management of cancer associated VTE at the end of life and no guidance when to stop anticoagulation for the imminent death in hospice care.
Methods
We retrospectively reviewed 153 VTE patients with advanced cancer who were treated with anticoagulation in our hospital from January 2016 to December 2022.
Results
Total 153 patients managed with anticoagulation for the treatment and secondary prevention for cancer associated VTE were enrolled. The median age of patients with 66 years and 69% of patients were female. The median duration of treatment with anticoagulation was 92.3 days. 42% of patients were receiving prophylactic anticoagulation, most frequently low molecular weight heparin. Of these patients, 47 patients continued anticoagulation therapy until death, 22 patients up to 7 days prior to death, 14 patients up to 28 days to 8 days and 15 patients over 1 month. Clinically relevant non-major bleeding was recorded 8 patients. However, bleeding rates increased closer impending death with 6 patients of bleeding in the last 7 days of life. No data were recorded suggestive of recurrence VTE or major bleeding. Despite specialized palliative consultation, at the time of death 30% of patients were still on prophylactic anticoagulation.
Conclusions
The majority of advanced cancer patients with VTE were managed with anticoagulation up to or within days of death in real world. Patients with poor performance status and short prognosis are unlikely to benefit from anticoagulation. Given the absence of guidelines about the use of anticoagulation in terminal cancer patients, it should be an early and multidisciplinary decision. It will be a strategy to improve a rational policy of anticoagulation and to prevent bleeding complication.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
39P - Prognostic significance of hypoxic microenvironment biomarkers in invasive ductal breast cancer
Presenter: Sungmin Kang
Session: Poster Display
Resources:
Abstract
40P - Intra-tumoral CD3, CD4, and CD8 as prognostic biomarkers in Asian breast cancer
Presenter: Jia Wern Pan
Session: Poster Display
Resources:
Abstract
41P - Brown fat activation demonstrated on FDG PET/CT predicts survival outcome
Presenter: Sonya Park
Session: Poster Display
Resources:
Abstract
42P - A promising anticancer drug for triple-negative breast cancer: OZ-001 suppresses tumor growth by dual targeting STAT3 and calcium signaling
Presenter: Jisun Kim
Session: Poster Display
Resources:
Abstract
43P - Performance evaluation of a combined risk model for breast cancer risk prediction in Indonesian population (TRIP Study)
Presenter: Marco Wijaya
Session: Poster Display
Resources:
Abstract
44P - Pathological complete response to neoadjuvant chemotherapy and outcomes in Her-2 negative locally advanced breast cancer
Presenter: Amrith Patel
Session: Poster Display
Resources:
Abstract
45P - Demographic determinants of pathological complete response after neoadjuvant chemotherapy in breast cancer
Presenter: Anvesh Dharanikota
Session: Poster Display
Resources:
Abstract
46P - Predicting toxicity following cancer chemotherapy by detecting transporter gene ABCB1 (C1236T, G2677T/A, C3435CT) polymorphism in breast cancer patients receiving chemotherapy with anthracycline and taxane either sequentially or concomitantly
Presenter: Tanuma Mistry
Session: Poster Display
Resources:
Abstract
47P - Sequencing of chemotherapy and surgery among older triple-negative and HER2-positive breast cancer patients with comorbidities
Presenter: Anvesh Dharanikota
Session: Poster Display
Resources:
Abstract
48P - The impact of preoperative axillary ultrasound on the false negative rate of sentinel lymph node biopsy in post neoadjuvant chemotherapy breast cancer patients
Presenter: Byshetty Rajendar
Session: Poster Display
Resources:
Abstract